George Scangos, Ph.D., has served as our President and Chief Executive Officer and as a member of our board of directors since January 2017. From July 2010 to December 2016, Dr. Scangos served as Chief Executive Officer and as a member of the board of directors of Biogen Inc., a publicly traded biopharmaceutical company focused on the treatment of serious diseases. From October 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer at Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer Biotechnology’s biological products. Before joining Bayer Biotechnology in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University. Dr. Scangos has served as a member of the board of directors of various publicly traded companies, including: Exelixis, Inc., since 1996; Agilent Technologies, Inc., a life sciences, diagnostics and applied chemical analysis company, since 2014; and Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2010. Dr. Scangos served as Chair of PhRMA in 2016, and as the Chair of the California Healthcare Institute in 2010. He was a member of the board of directors of the Global Alliance for TB Drug Development from 2006 until 2010. Dr. Scangos currently serves on the Board of Trustees of Cornell University and the Board of Overseers of the University of California, San Francisco. Dr. Scangos received his B.A. in Biology from Cornell University and a Ph.D. in Microbiology from the University of Massachusetts.
What is George A. Scangos' net worth?
The estimated net worth of George A. Scangos is at least $761,545.86 as of February 26th, 2024. Dr. Scangos owns 112,989 shares of Vir Biotechnology stock worth more than $761,546 as of November 20th. This net worth approximation does not reflect any other assets that Dr. Scangos may own. Learn More about George A. Scangos' net worth.
How do I contact George A. Scangos?
Has George A. Scangos been buying or selling shares of Vir Biotechnology?
George A. Scangos has not been actively trading shares of Vir Biotechnology over the course of the past ninety days. Most recently, George A. Scangos sold 17,722 shares of the business's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $11.65, for a transaction totalling $206,461.30. Following the completion of the sale, the director now directly owns 112,989 shares of the company's stock, valued at $1,316,321.85. Learn More on George A. Scangos' trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 13 times. They sold a total of 172,771 shares worth more than $1,697,054.16. The most recent insider tranaction occured on November, 5th when EVP Verneuil Vanina De sold 2,347 shares worth more than $22,226.09. Insiders at Vir Biotechnology own 15.6% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 11/5/2024.
